手机闹钟一响，李杰（化名）不得不立即暂停进行中的会议，对会议伙伴说声抱歉，马不停蹄地冲进卫生间往眼睛里滴药水。 这样"局促"的场景是李杰的常态。在他的手机上，每天有8个这样的闹钟，对应两种治疗干眼的滴眼液用药时间。为了保证两种滴眼液的用药间隔在15分钟 以上，他必须精准计算时间。很多时候，他得硬着头皮面对工作场合闹钟响起的尴尬，还要忍受不开空调的燥热，以及无法长时间专注工作的烦恼。 幸运的是，李杰看到了更好的解决办法。7月中旬，全球首款干眼鼻喷药物——酒石酸伐尼克兰鼻喷雾剂（OC-01）在中山大学附属第一医院和深圳市眼科 医院实现内地首批商业化处方落地。据悉，这款新药单支定价599元，首方患者是位忙碌的白领。 7月23日，中山大学附属第一医院眼科主任万鹏霞接受《每日经济新闻》记者采访。她表示，目前干眼没有特效药，但也绝不是绝症，"（患者有）希望能够 减少用药的种类，减少用药的频次，甚至最终脱离用药"。 首款干眼鼻喷雾剂来中国，"打工人"治疗意愿最强 从业20余年，万鹏霞见证了干眼患者在眼科门诊的占比跃升。十几年前，门诊干眼患者多为中重度病例；如今，年轻的轻度干眼患者数量变多，他们大多通 过网络自查发现自己的症 ...

Core Viewpoint - Jiangsu Hengrui Medicine Co., Ltd. has received approval from the National Medical Products Administration for its product, Perfluorohexyl Octanoate Eye Drops, aimed at treating Meibomian Gland Dysfunction (MGD) related dry eye [1][2]. Group 1: Product Information - Product Name: Perfluorohexyl Octanoate Eye Drops (SHR8058) [1] - Dosage Form: Ophthalmic preparation [1] - Specification: 3ml [1] - Registration Category: Reference to Class 3 generic drug [1] - Prescription Status: Prescription drug [1] - Approved Indication: Treatment of dry eye related to Meibomian Gland Dysfunction [1]. Group 2: Market Context - The prevalence of dry eye in China is reported to be between 21% and 30% [1]. - Clinical studies indicate that 69% to 86% of dry eye patients suffer from MGD, highlighting the need for targeted treatments [1]. - Current treatments for MGD lack a specific drug, emphasizing the demand for effective and safe therapeutic options [1]. Group 3: Product Development and Investment - The eye drops consist of 100% Perfluorohexyl Octanoate, which stabilizes the tear film and prevents excessive evaporation [2]. - The product can penetrate the Meibomian glands to dissolve viscous secretions, addressing MGD-related dry eye [2]. - The total research and development investment for the product has reached approximately 107.53 million yuan [2].